KEY POINTS
- This pooled analysis combined two independently randomized PROSINT phase II cohorts from the Champalimaud Centre in Portugal and Montefiore Medical Center in the United States. Sixty patients were randomized and treated, with 59 evaluable after one patient withdrew consent: 30 received 45 Gy in five fractions and 29 received 24 Gy in a single fraction. Eligible patients had localized intermediate-risk prostate adenocarcinoma, clinical T1c–T2c disease, PSA <20 ng/mL, and no nodal or distant metastases. Median follow-up was 60.2 months.
- Both treatment strategies used stringent prostate localization and urethral-sparing techniques. Planning incorporated CT/MRI, a 150-cm³ air-filled endorectal balloon, electromagnetic beacon tracking, and a 2-mm PTV margin. The five-fraction regimen delivered 9 Gy per fraction, while single-dose radiotherapy (SDRT) delivered 24 Gy once. Prophylactic tamsulosin was prescribed in both cohorts. Androgen deprivation therapy was prohibited at the Portuguese institution and permitted for up to six months at Montefiore, although only one patient received it.
- No treatment-related grade ≥3 genitourinary or gastrointestinal toxicity was observed. Across both treatment groups, the incidence was 0/59 (95% CI 0–6.1%). Acute grade 1 GU toxicity occurred in 53.3% after five fractions versus 75.9% after SDRT (p=0.103), while acute grade 1 GI toxicity occurred in 10.0% versus 24.1% (p=0.181). No acute grade 2 GU or GI events were recorded. A grade 3 ureteric stenosis after SDRT was adjudicated as unrelated to irradiation because it was associated with nephrolithiasis outside the treatment volume.
- Late low-grade urinary toxicity was numerically more frequent after single-fraction treatment. Grade 1 late GU toxicity occurred in 36.7% after five fractions versus 62.1% after SDRT, corresponding to HR 2.04 (95% CI 0.96–4.32; p=0.058). Grade 2 GU events occurred in 3.3% versus 10.3%, respectively, while late grade 2 GI toxicity occurred in one patient per arm. Across the full cohort, treatment-related grade ≥2 GU and GI toxicity affected 6.8% and 3.4%, respectively.
- Patient-reported urinary symptoms worsened transiently but recovered toward baseline in both groups. Median International Prostate Symptom Score (IPSS) increased from 8.5 to 12 one month after five-fraction SBRT and from 8.0 to 11 after SDRT. Model-estimated increases from baseline were 3.4 and 6.1 points, respectively, with a between-group difference of 2.7 points (95% CI −1.80 to 7.16). Longitudinal IPSS trajectories did not differ significantly (interaction p=0.733), although questionnaire completion was limited at later follow-up.
- Biochemical outcomes were encouraging but statistically imprecise. At 36 months, median PSA was 0.30 ng/mL after five fractions versus 0.36 ng/mL after SDRT. Eleven biochemical failures occurred, five and six, respectively. Estimated five-year biochemical relapse-free survival was 85.1% versus 80.5%, with HR 1.05 (95% CI 0.31–3.50; p=0.937). Unfavorable intermediate-risk disease accounted for 10 of 11 failures, with five-year biochemical control of 71.3% versus 95.8% in favorable intermediate-risk patients.
- The study was designed primarily for safety, not equivalence or noninferiority. Each center randomized patients independently, the pooled analysis had no prospective comparative efficacy sample-size calculation, and only 11 biochemical failures were observed. Differences in baseline risk distribution, institutional treatment schedules, and permitted ADT introduce additional uncertainty. The favorable safety findings also depend on a specialized platform incorporating intrafraction tracking, tight margins, and urethral-sparing measures that may not be available in all departments.
CLINICAL TAKEAWAY
Single-fraction 24-Gy prostate SBRT demonstrated acceptable long-term safety and sustained PSA suppression in this small randomized phase II experience. However, mild urinary toxicity was numerically more common, and the wide confidence intervals do not establish oncologic equivalence to five-fraction treatment. Single-fraction prostate radiotherapy remains investigational and requires adequately powered comparative trials.
SOURCE
International Journal of Radiation Oncology, Biology, Physics